Market Cap 12.57B
Revenue (ttm) 393.50M
Net Income (ttm) -409.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -103.97%
Debt to Equity Ratio -4.23
Volume 401,000
Avg Vol 468,818
Day's Range N/A - N/A
Shares Out 61.62M
Stochastic %K 92%
Beta 0.41
Analysts Strong Sell
Price Target $251.56

Company Profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candid...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 22 22 44
Address:
Tuborg Boulevard 12, Hellerup, Denmark
NVDAMillionaire
NVDAMillionaire Oct. 2 at 7:54 AM
$ASND Really good write-up that perfectly summarizes ASND's present situation. So if you want to bring your ASND knowledge up to date or just discover ASND, this is required reading. https://beyondspx.com/quote/ASND/analysis/ascendis-pharma-pioneering-rare-disease-therapies-with-transcon-innovation-nasdaq-asnd
0 · Reply
highnihilism
highnihilism Sep. 30 at 12:06 PM
$EWTX Edgewise Therapeutics: 28 trades, $21K vs $15K avg (1.36x). $16K calls / $5K puts. $FULC Fulcrum Therapeutics: 27 trades, $16K vs $54K avg (0.30x). $16K calls / $0 puts. $PACB Pacific Biosciences: 42 trades, $18K vs $34K avg (0.52x). $16K calls / $2K puts. $ASND Ascendis Pharma: 20 trades, $18K vs $383K avg (0.05x). $16K calls / $2K puts.
0 · Reply
Estimize
Estimize Sep. 29 at 11:03 AM
Wall St is expecting -0.34 EPS for $ASND Q3 [Reporting 11/13 AMC] http://www.estimize.com/intro/asnd?chart=historical&metric_name=eps&utm_c
0 · Reply
SweepCastApp
SweepCastApp Sep. 29 at 10:08 AM
$ASND: Unusual Options Activity Alerted CALL flow observed 43x contracts at Strike price of $210 Exp on 12/19/2025 with Premium of $41K and showing BEARISH Sentiment
0 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 11:14 AM
$ASND: TRADE CALL orders came through 316 @ 5, Strike 200.0, Exp 10/17/2025, Premium $158,000, Sentiment NEUTRAL
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Sep. 25 at 3:49 PM
$ASND $11.5B mc founder-led $XBI/$IBB name with a LOW VOLUME rinse into 10-week SMA this week. AI Council is BULLISH with a BUY recommendation here. Strong share stats (increasing pct of funds and decreasing short float long-term. Fundamentals also exceptional just 1413 watchers on @Stocktwits !
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Sep. 23 at 6:43 PM
$ASND hey room, what kind of pump we looking for going into pdufa in November ? @GreggTwits
1 · Reply
Quantumup
Quantumup Sep. 23 at 3:49 PM
UBS reiterated $ASND at a Buy rating, a $307 price target and said, $MBX's weekly canvuparatide meets primary endpoint & we think shows better data than investors expected, but we think $ASND still has clear leadership in the space. #HypoPARA2025 #InternationalHypoPara2025 $AZN $NVO UBS additionally said:
0 · Reply
Pika_Capital
Pika_Capital Sep. 22 at 6:58 PM
$ASND lol 🤡 s sold after weak $MBX data today. But recovering nicely.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Sep. 21 at 10:37 PM
List of all commercial-stage oncology & non-oncology (over $100MM MC) M&A for those with 1st FDA approvals going back to 1/1/2013. 88% of commercial-stage oncology sold at gains were sold within 2 years of FDA approval. It is 91% in non-oncology over 33 months. Because new drugs are worth the net present value of their future sales thru patent expiration, new drugs become less valuable over time as patent life is generally always nearing. Because approval rates are dismal, we can count on 2 hands commercial-stage bios that have scored a second approval of a drug with a meaningful commercial opportunity or a label extension. Of course there are exceptions like $ASND & $INSM but the odds are long. The evidence is overwhelming shareholders are best served via M&A exit as soon as possible after FDA approval. $IOVA & $GERN are textbook examples of new comm'l-stage bios with credible label extension potential. $INVA ? Pushback/feedback? This is not investment advice.
3 · Reply
Latest News on ASND
Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 2:46 AM EDT - 2 months ago

Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript


Ascendis Pharma Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:01 PM EDT - 2 months ago

Ascendis Pharma Reports Second Quarter 2025 Financial Results


FDA Accepts TransCon® CNP NDA for Priority Review

Jun 2, 2025, 8:00 AM EDT - 4 months ago

FDA Accepts TransCon® CNP NDA for Priority Review


Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

May 1, 2025, 9:35 PM EDT - 5 months ago

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript


Ascendis Pharma Reports First Quarter 2025 Financial Results

May 1, 2025, 4:01 PM EDT - 5 months ago

Ascendis Pharma Reports First Quarter 2025 Financial Results


Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 11:03 PM EST - 8 months ago

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript


Ascendis Pharma: Danish Blockbuster Hunter

Jan 29, 2025, 12:31 AM EST - 8 months ago

Ascendis Pharma: Danish Blockbuster Hunter


Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 10:53 PM EST - 11 months ago

Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript


Ascendis Pharma Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:01 PM EST - 11 months ago

Ascendis Pharma Reports Third Quarter 2024 Financial Results


Ascendis Pharma Takes A Big Price Cut On Skytrofa

Sep 5, 2024, 1:30 AM EDT - 1 year ago

Ascendis Pharma Takes A Big Price Cut On Skytrofa


Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript

Sep 3, 2024, 9:41 PM EDT - 1 year ago

Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript


NVDAMillionaire
NVDAMillionaire Oct. 2 at 7:54 AM
$ASND Really good write-up that perfectly summarizes ASND's present situation. So if you want to bring your ASND knowledge up to date or just discover ASND, this is required reading. https://beyondspx.com/quote/ASND/analysis/ascendis-pharma-pioneering-rare-disease-therapies-with-transcon-innovation-nasdaq-asnd
0 · Reply
highnihilism
highnihilism Sep. 30 at 12:06 PM
$EWTX Edgewise Therapeutics: 28 trades, $21K vs $15K avg (1.36x). $16K calls / $5K puts. $FULC Fulcrum Therapeutics: 27 trades, $16K vs $54K avg (0.30x). $16K calls / $0 puts. $PACB Pacific Biosciences: 42 trades, $18K vs $34K avg (0.52x). $16K calls / $2K puts. $ASND Ascendis Pharma: 20 trades, $18K vs $383K avg (0.05x). $16K calls / $2K puts.
0 · Reply
Estimize
Estimize Sep. 29 at 11:03 AM
Wall St is expecting -0.34 EPS for $ASND Q3 [Reporting 11/13 AMC] http://www.estimize.com/intro/asnd?chart=historical&metric_name=eps&utm_c
0 · Reply
SweepCastApp
SweepCastApp Sep. 29 at 10:08 AM
$ASND: Unusual Options Activity Alerted CALL flow observed 43x contracts at Strike price of $210 Exp on 12/19/2025 with Premium of $41K and showing BEARISH Sentiment
0 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 11:14 AM
$ASND: TRADE CALL orders came through 316 @ 5, Strike 200.0, Exp 10/17/2025, Premium $158,000, Sentiment NEUTRAL
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Sep. 25 at 3:49 PM
$ASND $11.5B mc founder-led $XBI/$IBB name with a LOW VOLUME rinse into 10-week SMA this week. AI Council is BULLISH with a BUY recommendation here. Strong share stats (increasing pct of funds and decreasing short float long-term. Fundamentals also exceptional just 1413 watchers on @Stocktwits !
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Sep. 23 at 6:43 PM
$ASND hey room, what kind of pump we looking for going into pdufa in November ? @GreggTwits
1 · Reply
Quantumup
Quantumup Sep. 23 at 3:49 PM
UBS reiterated $ASND at a Buy rating, a $307 price target and said, $MBX's weekly canvuparatide meets primary endpoint & we think shows better data than investors expected, but we think $ASND still has clear leadership in the space. #HypoPARA2025 #InternationalHypoPara2025 $AZN $NVO UBS additionally said:
0 · Reply
Pika_Capital
Pika_Capital Sep. 22 at 6:58 PM
$ASND lol 🤡 s sold after weak $MBX data today. But recovering nicely.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Sep. 21 at 10:37 PM
List of all commercial-stage oncology & non-oncology (over $100MM MC) M&A for those with 1st FDA approvals going back to 1/1/2013. 88% of commercial-stage oncology sold at gains were sold within 2 years of FDA approval. It is 91% in non-oncology over 33 months. Because new drugs are worth the net present value of their future sales thru patent expiration, new drugs become less valuable over time as patent life is generally always nearing. Because approval rates are dismal, we can count on 2 hands commercial-stage bios that have scored a second approval of a drug with a meaningful commercial opportunity or a label extension. Of course there are exceptions like $ASND & $INSM but the odds are long. The evidence is overwhelming shareholders are best served via M&A exit as soon as possible after FDA approval. $IOVA & $GERN are textbook examples of new comm'l-stage bios with credible label extension potential. $INVA ? Pushback/feedback? This is not investment advice.
3 · Reply
deinosuchusiscool
deinosuchusiscool Sep. 19 at 6:22 PM
$ASND incredibly obnoxious price action for way too long now.
0 · Reply
dogDazeSummer
dogDazeSummer Sep. 19 at 12:50 PM
$IFRX Technically the deck is clear of resistance to $1.80-$1.85, hit 4 times this year. RA, Ikarian and Adage scooped up all the 300-400k blocks from Feb secondary —-blown out with market orders on May 28th after PG “futility”, when 8m shares traded (2m directly into the open bonnet of Peter Kolchinski) How many days or hours until RA files 13G or 13D indicting 5%? In 1/2 of their 63 holdings, RA is a 10% owner. $ASND largest holding 29.89% of portfolio while newest add—-> Inflarx smallest at .0263% 3 of their holdings have been acquired this quarter. $VOR $TSHA RA has also sold 4 portfolio companies to $ABBV in last 12 months. All had pipeline potential. Next resistance $2 after we clear $1.80, then it gets fun What is a stock worth with 5-10x upside according to Guggenheim trading just over $?
1 · Reply
topstockalerts
topstockalerts Sep. 15 at 7:07 PM
BofA Global Research highlighted three biotech stocks with near-term catalysts. Ascendis Pharma : Price target $230. Key catalyst is Nov. 30 PDUFA for TransCon CNP in achondroplasia (90% success chance, $1.1B peak sales). Skytrofa launch in Q4 and Yorvipath uptake remain central. Analysts expect Ascendis to keep first-mover advantage over MBX. Kymera Therapeutics : Target $54. Phase 1b data in Q4 2025 for STAT6 degrader KT-621 in atopic dermatitis, aiming to show robust activity and early clinical benefit. IRF5 degrader KT-579 expected to start Phase 1 in early 2026. Merus : Target $92. Expanding petosemtamab beyond HNSCC. Initial Phase 2 colorectal cancer data due H2 2025, with comparisons to current EGFR therapies. Phase 3 HNSCC trials (LiGeR-HN1, LiGeR-HN2) to finish enrollment by end-2025, with data in 2026. $ASND $KYMR $MRUS
0 · Reply
Estimize
Estimize Sep. 15 at 11:06 AM
Wall St is expecting -0.32 EPS for $ASND Q3 [Reporting 11/13 AMC] http://www.estimize.com/intro/asnd?chart=historical&metric_name=eps&utm_c
0 · Reply
CaptainAmrica
CaptainAmrica Sep. 10 at 8:10 PM
I think we have 2 or 3 more weeks of down bias drift in the market then the rally fueled by tech, data and ai...Sold CRCL, APLD BMNR CRWV CWVX today...Rebought CRCL small amount ....Bullish on $GLXY.... Bot more $HON, $ASND, $CRSP...
0 · Reply
dogDazeSummer
dogDazeSummer Sep. 8 at 6:19 PM
$ASND Congrats on making yet another ATH! Always wonder if Ascendis will someday be part of $ABBV What a run from $17. RA Capital biggest holding: Ascendis 10,281,496 shares valued at $2B RA Capital Smallest & newest holding added last 13F 8/15/25 for Q2: Inflarx $IFRX 1,973,233 shares valued at $3M
0 · Reply
Thelonius_Stonk
Thelonius_Stonk Sep. 7 at 10:53 AM
$ASND beast
0 · Reply
Pika_Capital
Pika_Capital Sep. 5 at 7:11 PM
$ASND top position at the moment. She keeps running.
1 · Reply
WAJeff
WAJeff Sep. 5 at 4:53 PM
0 · Reply
StockConsultant
StockConsultant Sep. 3 at 12:21 PM
$ASND Ascendis Pharma stock, narrow range breakout
0 · Reply
JFDI
JFDI Sep. 2 at 7:29 PM
$ASND 200 b/o
0 · Reply
WAJeff
WAJeff Sep. 2 at 7:11 PM
$ASND $203.59 ath
0 · Reply